Barbara Ryan

What will current stranglehold mean for industry down the line?

But a doubling-down on R&D offers reason for optimism.

Biopharma stock performance continues to struggle.

Brief summary of EY’s 2022 M&A Firepower report highlights trends.

Industry growth in innovation could spark financial rebound.

Regulatory headwinds are poised to ease as new year approaches.

While Q3 numbers look bleak, is improvement on the horizon?

But could there be a shift in momentum?

A remarkable run indeed, but cost questions can’t be ignored.

What are the reasons behind the slump and what does the future hold?

Adding context to Pfizer’s orbit-busting, first-quarter earnings.

Amid vaccine heroics, its complex story may finally be resonating.

Dueling paths leave market fortunes uncertain.

Tone still set on the market catalysts to look for in 2021.

Vaccine strides, likely pricing impasse point to optimism for 2021.

Biopharma raises an unprecedented $100 billion.

When the people are the sole assets.

The key factors behind the sector’s strong surge in new equity fundraisings.

Latest reform brouhaha requires a united response focused on real solutions.

Embracing expanded digital models key to future ROI.

Now is the time, the world is listening.

Rocked by pandemic, can companies protect their bottom line?